A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
List view / Grid view
Post-traumatic stress disorder (PTSD)
A study has identified a protein complex elevated in PTSD patients and developed a peptide to disrupt it, preventing the recall of fear memories in early tests and paving the way for new therapies.
Researchers in the U.S. have identified a new link between epigenetic changes in the brains of rats and resulting translational control during fear memory reconsolidation.
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
17 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Recent studies show that sleep disturbance is not only a negative outcome from PTSD, it may also contribute to its onset...
4 August 2016 | By Niamh Marriott, Digital Content Producer
Chronos Therapeutics, a biotech company researching ageing diseases, brain and nervous system disorders, have announced the appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl, as Vice Presidents of Pre-Clinical Development...
28 October 2015 | By Victoria White
Experimentally reducing SGK1 activity in rats induced learned helplessness ( a behaviour thought to mimic one aspect of PTSD), while overexpressing the protein reduced it...
17 August 2015 | By Victoria White
Genetically altered mice could form the basis for research into new treatments for cognitive disorders such as Alzheimer’s disease and schizophrenia...